Detecting heart issues in cancer survivors
CAncer Survivor CArdiomyopathy DEtection Pilot Study
Mayo Clinic · NCT05201014
This study is testing if using AI and blood tests can help find heart problems in adult cancer survivors who have had certain chemotherapy treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Mayo Clinic (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT05201014 on ClinicalTrials.gov |
What this trial studies
This observational study aims to enhance cardiovascular care for adult cancer survivors by evaluating the effectiveness of AI-ECG and NT-pro-BNP in identifying left ventricular dysfunction after anthracycline chemotherapy. The study will gather data to establish a nationwide screening program for long-term monitoring of heart health in this population. Participants will undergo various cardiac assessments, including echocardiograms and blood tests, to determine optimal diagnostic thresholds.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who have been diagnosed with breast cancer, lymphoma, or sarcoma and are either currently undergoing or have completed anthracycline therapy.
Not a fit: Patients with a history of significant heart conditions, such as cardiomyopathy or heart failure, or those with implanted electronic devices will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and management of heart problems in cancer survivors, ultimately enhancing their quality of life.
How similar studies have performed: Other studies have shown promise in using similar diagnostic approaches for monitoring cardiovascular health in cancer survivors, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥18 years of age prior to enrollment and anthracycline start date * Diagnosis of breast cancer, lymphoma, or sarcoma with either planned or at 1 year after completion of anthracycline therapy, including patients from 6-12 months and greater than 1 year post-anthracycline exposure. * Patients with a history of persistent atrial fibrillation (afib) that are not in afib remission. Include if the most recent ECG does not show afib. Atrial flutter treated the same Exclusion Criteria: * LVEF \<50% or prior confirmed history of cardiomyopathy, heart failure, left bundle branch block, or paced rhythm * Patients with a history of persistent atrial fibrillation (afib) that are not in afib remission. Include if the most recent ECG does not show afib. Atrial flutter treated the same. * Individuals with pacemakers, defibrillators, or other implanted electronic devices * Inability/unwillingness of individual to give written informed consent
Where this trial is running
Rochester, Minnesota
- Mayo Clinic in Rochester — Rochester, Minnesota, United States (RECRUITING)
Study contacts
- Principal investigator: Joerg Herrmann, MD — Mayo Clinic
- Study coordinator: Tiffany Hansen
- Email: Hansen.Tiffany@mayo.edu
- Phone: 507-293-0196
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cardiovascular Diseases, Cancer